Amai Proteins

Market position

Amai is positioned within the Israeli food-tech and precision fermentation sector as a developer of protein-based sugar alternatives for the mass food market, comparable to other Israeli fermentation and alternative-protein companies such as Remilk, Imagindairy and Brevel. The broader alternative protein sector has seen a sharp funding contraction, with total investment of $881M in 2025 — below $1B for the first time since 2018 — and fermentation companies experiencing a 43.5% decline, alongside a wave of consolidation, insolvencies and closures across the category.

Amai's stated differentiation is the redesign of naturally occurring hyper-sweet proteins so they meet mass-market food industry requirements — sugar-like sensory profile, high-temperature stability, long shelf life and low cost — rather than using the natural proteins as found, which the company says cannot be grown or manufactured cost-effectively. It also cites the integration of computational protein design, precision fermentation and in-house food technology and sensory evaluation in a single platform, and describes production via breweries as enabling distributed, cost-effective manufacturing and lower transportation costs.

Technology

The Pro3 Platform pairs AI Computational Protein Design (AI-CPD) with cloud computing, bioinformatics, molecular biology and protein engineering to redesign naturally occurring hyper-sweet proteins, then produces them via precision fermentation using brewery infrastructure, with in-house food technology and sensory evaluation to fit end applications. The platform is organized around four stated pillars: Pro-Taste, Pro-Planet, Pro-Health and Pro-Industry. The company's flagship output, sweelin®, is a monellin-based, zero-calorie, 100% protein sweetener.

Go-to-market

Amai sells to food and beverage manufacturers, supported by a business development and marketing team drawn from ingredient and nutrition multinationals such as DSM, Glanbia, DuPont, Unilever and Hershey. It builds visibility through industry trade shows (SupplySide West, Future Food-Tech), podcasts and media features, industry consortia with large food companies, and regulatory milestones such as FDA GRAS notification that enable customer adoption in the U.S.

Food and beverage manufacturers reformulating products to reduce added sugar, across soft drinks, juices, iced teas, dairy and alternative dairy, sauces and ketchup, spreads and dressings, snacks, chocolate, peanut butter, energy bars and functional foods.

Geography

Headquartered in Rehovot, Israel, with commercial activity targeting the United States — including a dedicated North America sales and business development role, participation in SupplySide West in Las Vegas and Future Food-Tech in San Francisco, and pursuit of U.S. FDA regulatory clearance. The company has also participated in European initiatives through the EU fund EIT Food.

History

The company was founded in 2016 and is based in Rehovot, Israel. It won the Global Wellness Summit startup competition in 2020 (first of 84 startups) and was named Grand Winner of the Extreme Tech Challenge in 2022. Its work was featured in a Nature Biotechnology article in 2023 and in a BBC StoryWorks 'Food for Thought' documentary series the same year. In October 2024 it announced multiple regulatory approvals for sweelin®, and in December 2024 reported completing a human clinical trial on the effects of sweet proteins. A safety evaluation of sweelin® was published in the Journal of Applied Toxicology in March 2025, and in February 2026 the company announced FDA GRAS notification for the ingredient.

Risks & controversies

The company operates in a sector undergoing significant contraction: analysis of the alternative protein industry counted at least 82 businesses acquired, merged, insolvent or shut down since September 2024, with investors reporting a shift toward companies with proven product-market fit and profitability. Commercialization also depends on regulatory clearances in each market, a process Amai has been pursuing since 2024.